, /PRNewswire/ -- , the leading provider of psychedelic therapy, announced today the findings of the in the history of ketamine therapy and psychedelic medicine. The study was published in the and was authored by psychiatrists and researchers from , NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom. Key Findings: "Millions of Americans are suffering from mental illness, and haven't been helped by traditional treatments," said co-author and Mindbloom Medical Director Dr.
. "This study confirms that at-home ketamine therapy can be an effective and fast-acting treatment for depression and anxiety, and shows why psychedelic therapy is going to be a first-line treatment in the next few years." The authors noted that the extensive support offered through Mindbloom – including 1:1 coaching, therapeutic content, and group integration – drives the effectiveness and safety of the treatment.
In addition, Mindbloom's at-home ketamine therapy programs overcome barriers like cost, provider availability, and stigma that prevent people from accessing effective mental health care. "Mindbloom's programs are successful because of our at-home model, not in spite of it," said Mindbloom's Founder and CEO . "Telehealth makes treatment more accessible and affordable, allowing clients to heal from the comfort of home.
Since our launch in 2019, people have questioned whether ketamine therapy could be delivered safely and effectively at home through teleh.